TickerTalks
Browse all tickers →
TickerTalks›$CDNA
CDCDNA

CareDx, Inc

$CDNA·$2.4B·Medical - Diagnostics & Research·Healthcare
$49.79-4.9%YTD+149.9%1Y+279.8%
Mentions · last 7 days
2026-08-21: 10 posts2026-08-22: 6 posts2026-08-23: 3 posts2026-08-24: 11 posts43+26%
Price updated 2d ago·X counts updated 6d ago
CDCDNA
$CDNACareDx, Inc
$49.79-4.91%43 posts+26%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CDNA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-08-26

The move is getting stronger, with heavier trading behind it.

CareDx is up 298% t12m at 99% of range — the transplant-diagnostics business is scaling hard while insiders take moderate profits.

CareDx Inc. is the transplant-medicine molecular-diagnostics company (AlloSure, AlloMap, AlloHeme) whose stock has run 298% over 12 months as the operating story finally caught up to the platform investment. The tape is at fresh 52-week highs.

  • The fundamentals are inflecting hard: last two prints delivered EPS beats of 59% (Q2) and 209% (Q1), revenue $118M with 69% gross margin — a diagnostics platform delivering that beat cadence with 90% EBITDA-to-FCF conversion (per bull thesis) supports the accelerated re-rating from broken-story to compounder.
  • The technical setup is confirming: bulls describe CDNA as 'a very pretty chart within biotech $XBI land,' with Blue Water Life Science increasing position, Upticken's 20/20 growth-with-leadership scan flagging CDNA, and modeled path to $75 PT by end-2027 on ~$575M revenue — that's a specific analytical framework supporting the tape.
  • The tape is fully extended: at 99% of the 52-week range, 38% above the 50-day and 114% above the 200-day on 1.44x elevated volume with beta 2.42 — a stock more than tripling t12m with the tape at fresh 52-week highs on above-average volume is genuine momentum; insider sales (Novack, Bickerstaff, Cournoyer) totaling ~$1.8M at $46 are moderate post-run distribution but not conviction-shifting.

The path if this works is the Nov 3 Q3 print delivering another clean beat plus concrete AlloSure/AlloMap prescription-growth commentary, taking the tape past $65. What breaks it is a soft-transplant-test-volume signal or a fresh reimbursement-pressure event — CDNA is priced for continued acceleration, and any operational stumble compresses the multiple.

Agrees with X sentimentThe X bulls have the setup right — CDNA as 'very pretty chart within biotech $XBI land,' Blue Water Life Science increasing position, Upticken's 20/20 growth-with-leadership scan flagging CDNA, $75 PT by end-2027 on ~$575M revenue with 90% EBITDA-to-FCF conversion, $46.50 support with $47.50 15-min closes as sizing triggers — and mechanics back the accelerating tape.

What to watch: Nov 3 Q3 print (sell-side EPS $0.24) — a clean beat plus concrete AlloSure/AlloMap prescription-growth commentary extends the tape past $65; a soft-transplant-test-volume signal or a fresh reimbursement-pressure event breaks the accelerating tape back to $35.

On the calendar: 2026-11-03 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment11 posts analyzed · as of 2026-08-30

The mood is bullish on CareDx — chartists flag a "textbook High Tight Flag" in the genomics/diagnostics theme, RS new highs and a close at highs-of-day showing strength as the name breaks out of its base. Fundamentally, one long lays out a $75 target by end 2027 on roughly $575M of revenue and $105M of free cash flow, calling ~24x forward FCF "far too cheap" for a ~15% grower with no debt and over $370M in cash. Blue Water Life Science 13F also added CDNA.

Read the AI verdict + X sentiment for $CDNA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Transplant diagnostics company using donor-derived cell-free DNA testing to monitor organ rejection risk post-transplant.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $CDNA.

Medical - Diagnostics & Research · Healthcare

Diagnostic testing volumes are normalizing post-COVID elevated baseline; liquid biopsy and genomic sequencing are the structural growth areas. Reimbursement rate changes (CMS updates) are the primary margin risk for established lab businesses.

What this means for $CDNA

Partial — software subscription economics provide some insulation from macro cycles; AI integration is the growth catalyst for this segment; CareDx, Inc.

Industry benchmark

21-name peer basket
+30.1%YTD
+70.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-255.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-3.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-3.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-2.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
68.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$0.37$0.23+59.4%
Q1 2026Apr 28, 2026$0.34$0.11+209.1%
Q4 2025Feb 24, 2026$0.12$0.02+503.0%
Q3 2025Nov 4, 2025$0.03$-0.08+138.9%
Next earningsTue, Nov 3·consensus EPS $0.24

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$117.7M+39.0%71.4%1.5%$0.05$514K
Q4 FY25$108.4M+25.2%66.6%-5.4%$-0.08$19.7M
Q3 FY25$100.1M+20.7%68.7%2.0%$0.03$36.1M
Q2 FY25$86.7M-6.1%66.9%-12.8%$-0.16$8.9M

Forward consensus

3-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$455.9M$455.5M – $456.3M$0.93$0.88 – $0.973
FY27$481.3M$481.0M – $481.5M$1.13$1.07 – $1.185
FY28$507.2M$474.1M – $540.3M$1.53$1.45 – $1.592

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+29.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+105.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 49.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.425-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 5Novack Jeffrey AdamSecretary and General Counsel2.7K sh$124KSellAug 5George BickerstaffDirector20.0K sh$926KSellAug 4Christine CournoyerDirector16.0K sh$751KSellAug 4Michael GoldbergDirector44.7K sh$2.1MSellJul 16Hannah ValantineDirector28.8K sh$1.0MSellJul 16Hanna John Walter JrCEO118.0K sh$4.5MSellJun 29Hanna John Walter JrCEO39.9K sh$1.2MSellJun 26Hanna John Walter JrCEO100 sh$3KSellJun 15Hanna John Walter JrCEO17.7K sh$425KSellJun 15Hannah ValantineDirector12.1K sh$280K
1–10 of 16
+ 31 other (13 inkinds · 10 awards · 8 exempts) in window

See when $CDNA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

CDNA (CDNA) reported financial results for quarter ended June 30, 2026 via 8-K Item 2.02, filed 2026-07-30. Full financials are in the attached press release (Exhibit 99.1). Quarterly earnings contain headline P&L, balance sheet, and guidance. Investors should review the exhibit for revenue, margins, EPS, and any updates to full-year outlook.

8-KAcquisition completedJul 78-K — Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

CareDx (CDNA) completed two back-to-back portfolio transactions: (1) sold CareDx AB (Swedish subsidiary, kitted lab products business) to Eurobio Scientific for $171.7M cash on June 30, 2026; (2) acquired Naveris Inc. via merger for $161.8M cash on July 1, 2026. The net cash effect is roughly neutral (~$10M outflow pre-adjustments), but the deal pair reshapes CareDx — divesting kitted diagnostics while acquiring Naveris's capabilities. Transformative back-to-back portfolio realignment executed within two days.

8-KOfficer or director changeJun 158-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

At CareDx's (CDNA) June 11, 2026 Annual Meeting (93% quorum, ~48.1M shares), shareholders approved a 1,600,000 share increase (~3.1% dilution) to the 2024 Equity Incentive Plan, effective upon stockholder approval. The plan amendment was previously adopted by the board April 21, 2026. Routine annual meeting vote with modest dilutive impact from the equity plan expansion.

S-3ASRAuto-shelf registrationApr 28S-3ASR
8-KMaterial agreementApr 288-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-K/AOfficer or director change (amended)Apr 238-K/A — Item 5.02: Officer or director change
8-KMaterial agreementApr 168-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 12 other (5 13Gs · 3 proxys · 2 10-Qs · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CareDx (CDNA) is a Great Momentum Stock: Should You Buy?zacks.com·4d agoBamco Inc. NY Makes New $55.21 Million Investment in CareDx, Inc. $CDNAdefenseworld.net·4d agoZacks Industry Outlook CareDx, BrightSpring and PACSzacks.com·6d ago3 Medical Service Stocks Resilient Amid Persistent Workforce Shortagezacks.com·7d agoRon Baron Trims CareDx Inc (CDNA) Stake -- Shares Trade 86% Above GF Valuegurufocus.com·10d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$TWST$PSNL$A$ILMN$NTRA$GH$TMO
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport